SCHEMBL3341283

SCHEMBL3341283

NC(=O)c1ccc2c(Br)[c]ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 17/20 0.41
PTPN1 P18031 1/20 0.37
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341422 0.81 GRM2 (0.41) GRM2PIM1
SCHEMBL3340403 0.77 GRM2 (0.36) GRM2PIM1
SCHEMBL4484391 0.74 GRM2 (0.35) GRM2PTPN1PIM1
SCHEMBL3922658 0.68 PIM1 (0.41) GRM2PTPN1PIM1
SCHEMBL4819768 0.68 GRM2 (0.47) GRM2PIM1
SCHEMBL11973236 0.68 PIM1 (0.38) GRM2PIM1
SCHEMBL3002690 0.67 PIM1 (0.39) PIM1
SCHEMBL759037 0.67 GRM2 (0.70) GRM2
SCHEMBL20264856 0.67 GRM2 (0.42) GRM2PIM1
SCHEMBL18343855 0.66 PIM1 (0.38) GRM2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 US claimed
EP-2393781-B1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 US disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS P2RY1, P2RX1, P2RX3 GRM2 496/4885PTPN1 1428/4885PIM1 3936/4885
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS P2RY1, P2RX3, P2RX1 GRM2 337/4885PTPN1 910/4885PIM1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.